# Infant Bacterial TherapeuticsB

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/infantbacterialtherapeuticsb).

## Overview

Infant Bacterial Therapeutics AB is a Stockholm-based biopharmaceutical company focused on developing and commercializing medicines for diseases affecting premature infants. Its core program is IBP-9414, a live biotherapeutic product based on a human bacterial strain, alongside earlier-stage candidates for other neonatal and pediatric conditions.

## Products & services

• IBP-9414 for prevention of necrotizing enterocolitis (NEC)
• Live Biotherapeutic Product development platform
• IBP-1016 for gastroschisis
• IBP-1118 for retinopathy of prematurity (ROP)
• IBP-1122 for VRE-related hospital infections

- **IBP-9414** (70%) — Late-stage neonatal therapy based on L. reuteri for preventing NEC in premature infants.
- **Pipeline candidates** (30%) — Earlier-stage programs including IBP-1016, IBP-1118 and IBP-1122.

- IBP-9414 for prevention of necrotizing enterocolitis (NEC)
- Live Biotherapeutic Product development platform
- IBP-1016 for gastroschisis
- IBP-1118 for retinopathy of prematurity (ROP)
- IBP-1122 for VRE-related hospital infections

## Customers

IBT does not sell a broad commercial product portfolio today; its primary customers are expected to be hospitals, neonatal intensive care units, and healthcare systems that treat premature infants. In the development phase, the company also depends on regulators and clinical investigators, since approval and clinical evidence are prerequisites for eventual adoption by clinicians and payers.

- **Neonatal hospitals and NICUs** (primary) — Would use IBP-9414 to reduce NEC risk and related complications in premature infants.
- **Regulators and health authorities** (primary) — Review clinical data and determine whether the product can be marketed.
- **Clinicians and neonatal specialists** (secondary) — Influence adoption by selecting therapies for high-risk preterm infants.
- **Healthcare payers and hospital procurement** (secondary) — Would evaluate clinical value and reimbursement once commercialization starts.

- Neonatal intensive care units treating premature infants
- Hospitals and healthcare systems adopting neonatal therapies
- Regulators evaluating safety and efficacy evidence
- Clinicians seeking therapies for NEC and related complications
- Future payers and procurement bodies if commercialization begins

## Geography

IBT is domiciled in Stockholm, Sweden and listed on Nasdaq Stockholm. Its business is globally oriented because the lead program is being developed for regulatory review in the United States and Europe, and the company’s cost base is exposed mainly to USD and EUR.

- **Sweden** (100%) — Corporate domicile and listing base; no revenue geography disclosed.

- Headquartered in Stockholm, Sweden
- Listed on Nasdaq Stockholm (IBT B)
- Primary regulatory focus on the US and Europe
- Development spending exposed mainly to USD and EUR
- Commercial footprint will depend on future approvals

## Strategy

IBT’s strategy centers on advancing IBP-9414 through the regulatory pathway and preparing for potential commercialization in premature-infant care. The company also maintains a broader neonatal pipeline to extend its platform beyond the lead asset and address additional rare pediatric indications.

- **Regulatory approval for IBP-9414** (short-term) — Marketing authorization is the key value-creation step for the lead asset.
- **Commercial readiness and supply chain** (short-term) — A biologic for premature infants requires reliable contract manufacturing and quality control.
- **Pipeline diversification** (medium-term) — Additional programs reduce dependence on a single asset and extend the platform.

- Advance IBP-9414 through FDA and EMA review
- Build evidence from the Phase III Connection Study
- Prepare manufacturing capacity for commercial volumes
- Maintain optionality through additional neonatal programs
- Use external expertise for regulatory and clinical design

## Risks

IBT is highly dependent on the success of IBP-9414 and on obtaining marketing authorization from the FDA and/or EMA. As a development-stage biotech, it also faces clinical, regulatory, manufacturing, and product-liability risks, while its cost base is sensitive to foreign-exchange movements in USD and EUR.

- **Regulatory approval failure for IBP-9414** [critical] — The company’s value depends heavily on FDA/EMA authorization for the lead asset.
- **Clinical development risk** [high] — Late-stage data may not translate into approval or commercial uptake.
- **Foreign exchange volatility** [medium] — Most development costs are incurred in foreign currencies, especially USD and EUR.
- **Contract manufacturing dependence** [high] — IBT relies on external manufacturers for commercial-scale supply and quality compliance.
- **Product liability and insurance limits** [medium] — Neonatal therapies and clinical trials can create claims if adverse events occur.

- Approval risk: lead asset may fail to obtain marketing authorization
- Clinical risk: trial data may not support efficacy or safety claims
- Manufacturing risk: contract manufacturers must meet quality and supply needs
- FX risk: development costs are exposed to USD and EUR
- Key-person risk: small organization depends on specialized personnel

## Accounting

IBT is a development-stage company with no net sales reported in the cited period, so reported results are driven by research, development, and foreign-exchange effects. Investors should watch how currency investments are marked, how clinical and regulatory costs are expensed, and how lease accounting is handled under the company’s chosen reporting framework.

- **Foreign-currency investments and FX effects** — Can materially move reported operating loss quarter to quarter
- **Research and development expense recognition** — Drives reported losses before commercialization
- **Lease accounting policy** — Affects balance sheet leverage and EBITDA comparability
- **No revenue recognition yet** — Commercial launch will introduce revenue recognition judgment

- No revenue yet; results are driven by R&D expense
- FX gains/losses on currency investments affect operating profit
- Clinical and regulatory spending is expensed as incurred
- Lease payments are recognized straight-line, not under IFRS 16
- Future approval milestones may affect timing of commercialization

---

*Last updated: 2026-08-11T04:04:53.420536+00:00*